An association between the cyclin D1 overexpression and therapeutic response to drugs, such as tamoxifen in breast cancer patients [64] and combined chemotherapy of erlotinib and bexarotene in lung cancer patients, was identified in clinical studies [57]. Here, CCND1 is linked to breast carcinoma.